

---

## FUTURE PLANS AND USE OF [REDACTED]

---

### FUTURE PLANS AND PROSPECTS

See “Business — Business Strategies” for a detailed description of our future plans.

### USE OF [REDACTED]

We estimate that we will receive [REDACTED] from the [REDACTED] of approximately HK\$[REDACTED] after deducting the [REDACTED], fees and estimated expenses payable by us in connection with the [REDACTED], assuming no exercise of the [REDACTED] and an [REDACTED] of HK\$[REDACTED] per Share, being the mid-point of the indicative [REDACTED] range stated in this document.

Assuming an [REDACTED] at the mid-point of the indicative [REDACTED] range, we intend to apply our [REDACTED] for the following purposes, subject to changes in light of our evolving business needs and changing market conditions.

- approximately HK\$[REDACTED] (representing [REDACTED]% of the [REDACTED]) will be allocated to fund the commercialization of our innovative products, primarily including bimekizumab and zuberitamab, as well as our other established drug portfolio;
- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], for the commercialization activities for bimekizumab for the next three years, taking into account its anticipated new indication expansion in 2026 primarily including (i) sales and marketing team expansion; (ii) marketing activities for its approved indications; and (iii) preparation for the commercial activities for its new indications, among others;
- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], for the commercialization activities for zuberitamab for the next two years, primarily including sales and marketing team expansion and marketing activities for its approved indications;
- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], for the commercialization activities for other established drug portfolio;
- approximately HK\$[REDACTED] (representing [REDACTED]% of the [REDACTED]) will be used to fund the ongoing R&D of our pipeline products, including BR2251, BRY812, BR111 and other IND-enabling preclinical drug candidates, including
  - approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], will be used to fund the R&D activities for BR2251. We anticipate that these allocations will primarily support (i) its phase 2 and phase 3 clinical trial in China for primary gout for the next five years; (ii) the China arm of its phase 3 MRCT for refractory gout and tophaceous gout for the next five years.

---

## FUTURE PLANS AND USE OF [REDACTED]

---

- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], will be used to fund the R&D activities for BRY812. We anticipate that these allocations will primarily support its ongoing phase 1b clinical trial, phase 2 and phase 3 clinical trials in China across multiple indications for the next five years.
- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], will be used to fund the R&D activities for BR111. We anticipate that these allocations will primarily support its process optimization, its phase 1 and pivotal clinical trial across multiple oncology indications including DLBCL and solid tumors for the next five years.
- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], will be used to fund the R&D activities for BR113. We anticipate that these allocations will primarily support its phase 1a & 1b study, phase 2b studies and phase 3 studies in solid tumor indications for the next five years.
- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], will be used to fund the R&D activities for BR2060. We anticipate that these allocations will primarily support its CMC optimization, phase 1 through phase 3 studies across multiple indications and clinical pharmacology studies including drug-drug interaction, food effect and mass balance studies for the next five years.
- approximately [REDACTED]% of our [REDACTED], or HK\$[REDACTED], will be used to fund the R&D activities for other IND-enabling studies and phase 1 and 2 studies for certain preclinical candidates, including BR2047 and BR1274.
- approximately HK\$[REDACTED] (representing [REDACTED]% of the [REDACTED]) will be used to fund the continued development of our technology platforms, underpinning our future exploration and development of new drug candidates;
- approximately HK\$[REDACTED] (representing [REDACTED]% of the [REDACTED]) will be used for potential investments and business development opportunities in the field of immunology. We primarily identify assets that have generated favorable pre-clinical and clinical data that can achieve synergies with our existing products. According to Frost & Sullivan, there are a significant number of assets available that can meet this criteria. As of the Latest Practicable Date, we had not identified any specific investment targets.
- approximately HK\$[REDACTED] (representing [REDACTED]% of the [REDACTED]) will be used to further strengthen our operation capabilities, including (i) upgrading our data management, and digital infrastructure systems to enhance operational efficiency and data security; (ii) implementing AI-powered platforms and solutions to support drug discovery and enterprise-wide applications; and (iii) upgrading business systems across our commercial, research and development, and manufacturing operations to support business growth.

---

## FUTURE PLANS AND USE OF [REDACTED]

---

- approximately HK\$[REDACTED] (representing [REDACTED]% of the [REDACTED]) will be used for our working capital and general corporate purposes.

The above allocation of the [REDACTED] from the [REDACTED] will be adjusted on a pro rata basis in the event that the [REDACTED] is fixed at a higher or lower level compared to the mid-point of the indicative [REDACTED] range stated in this document. If the [REDACTED] is exercised in full, the [REDACTED] that we will receive will be approximately HK\$[REDACTED], assuming an [REDACTED] of HK\$[REDACTED] per Share (being the mid-point of the indicative [REDACTED] range), in which case we intent to apply the additional [REDACTED] to the above purposes according to the stated proportions.

To the extent that the [REDACTED] from the [REDACTED] are not immediately used for the purposes described above and to the extent permitted by the relevant laws and regulations, they will be placed in short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance or the applicable laws and regulations in other jurisdictions). We will issue an appropriate announcement if there is any material change to the above proposed use of [REDACTED].